Alnylam Pharmaceuticals Stock Current Valuation
| ALNY Stock | USD 145.16 0.16 0.11% |
Valuation analysis of Alnylam Pharmaceuticals helps investors to measure Alnylam Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to rise to -107.35 in 2024. Enterprise Value Multiple is likely to rise to -107.35 in 2024. Fundamental drivers impacting Alnylam Pharmaceuticals' valuation include:
Price Book 142.9249 | Enterprise Value 18.7 B | Enterprise Value Ebitda (81.96) | Price Sales 10.2709 | Enterprise Value Revenue 9.6506 |
Undervalued
Today
Please note that Alnylam Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Alnylam Pharmaceuticals is based on 3 months time horizon. Increasing Alnylam Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Alnylam Pharmaceuticals is useful when determining the fair value of the Alnylam stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Alnylam Pharmaceuticals. Since Alnylam Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Alnylam Stock. However, Alnylam Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 145.16 | Real 169.13 | Target 229.39 | Hype 145.65 | Naive 140.1 |
The real value of Alnylam Stock, also known as its intrinsic value, is the underlying worth of Alnylam Pharmaceuticals Company, which is reflected in its stock price. It is based on Alnylam Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Alnylam Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Alnylam Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Alnylam Pharmaceuticals helps investors to forecast how Alnylam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Alnylam Pharmaceuticals more accurately as focusing exclusively on Alnylam Pharmaceuticals' fundamentals will not take into account other important factors: Alnylam Pharmaceuticals Company Current Valuation Analysis
Alnylam Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Alnylam Pharmaceuticals Current Valuation | 18.72 B |
Most of Alnylam Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alnylam Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alnylam Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Alnylam Pharmaceuticals is extremely important. It helps to project a fair market value of Alnylam Stock properly, considering its historical fundamentals such as Current Valuation. Since Alnylam Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alnylam Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alnylam Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Alnylam Pharmaceuticals has a Current Valuation of 18.72 B. This is 30.35% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 12.62% lower than that of the firm.
Alnylam Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alnylam Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics of similar companies.Alnylam Pharmaceuticals is currently under evaluation in current valuation category among related companies.
Alnylam Fundamentals
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0478 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 18.72 B | ||||
| Shares Outstanding | 126.45 M | ||||
| Shares Owned By Insiders | 0.41 % | ||||
| Shares Owned By Institutions | 95.02 % | ||||
| Number Of Shares Shorted | 2.8 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 142.92 X | ||||
| Price To Sales | 10.27 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 868.6 M | ||||
| EBITDA | (228.12 M) | ||||
| Net Income | (440.24 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 2.68 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | (1.75) X | ||||
| Cash Flow From Operations | 104.16 M | ||||
| Short Ratio | 3.86 X | ||||
| Earnings Per Share | (3.53) X | ||||
| Price To Earnings To Growth | (0.49) X | ||||
| Target Price | 222.68 | ||||
| Number Of Employees | 2.1 K | ||||
| Beta | 0.4 | ||||
| Market Capitalization | 18.55 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | (7.01 B) | ||||
| Working Capital | 2.01 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
| Net Asset | 3.83 B |
About Alnylam Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Alnylam Pharmaceuticals Investors Sentiment
The influence of Alnylam Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Alnylam. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Alnylam Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alnylam Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alnylam Pharmaceuticals' short interest history, or implied volatility extrapolated from Alnylam Pharmaceuticals options trading.
Pair Trading with Alnylam Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Alnylam Stock
| 0.77 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.74 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.7 | MRSN | Mersana Therapeutics Downward Rally | PairCorr |
| 0.59 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.57 | INZY | Inozyme PharmaInc Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alnylam Pharmaceuticals Piotroski F Score and Alnylam Pharmaceuticals Altman Z Score analysis. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.53) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.